Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis

This study moved lipoprotein(a) from a risk factor for having aortic stenosis to a driver of how fast the disease worsens — a distinction that matters enormously for patients already diagnosed.

Following 220 patients with aortic stenosis, the investigators found that those in the top tertile for Lp(a) and for oxidized phospholipids on apoB experienced significantly faster narrowing of the valve and were about twice as likely to be rapid progressors heading toward valve replacement. The two markers were tightly correlated, fitting the mechanism that Lp(a) carries inflammatory oxidized phospholipids into the valve. Most striking was an age interaction: in patients 57 or younger, high Lp(a) was an especially powerful predictor of rapid progression.

The clinical resonance is direct. It identifies a measurable subgroup whose valve disease will likely advance quickly, and it provides the rationale for testing Lp(a)-lowering therapies as a way to slow a disease that currently can only be treated by replacing the valve.

We rate the evidence strong. A well-conducted prospective cohort with a clear mechanistic underpinning, it is among the more clinically pointed pieces of the Lp(a)–valve literature.